Ohman E M, Christenson R H, Califf R M, George B S, Samaha J K, Kereiakes D J, Worley S J, Wall T C, Berrios E, Sigmon K N
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
Am Heart J. 1993 Oct;126(4):819-26. doi: 10.1016/0002-8703(93)90694-5.
Coronary artery patency after thrombolytic therapy has important prognostic implications for survival after acute myocardial infarction. The ability to noninvasively identify patients early after thrombolysis may therefore allow other strategies, such as adjunctive therapy or rescue angioplasty, to be used to restore patency of the infarct-related artery. This study examined the use of a rapid creatine kinase (CK)-MB assay in conjunction with selected clinical variables for noninvasive detection of reperfusion after thrombolysis. Patients were enrolled in a study evaluating accelerated plasminogen activator dose regimens with patency assessments by first angiographic injection during acute angiography at a median and interquartile range (25th and 75th percentiles) 142 (96,195) minutes after starting thrombolytic therapy. Serum CK-MB samples measured by a rapid dual monoclonal antibody assay were obtained in 207 patients before (baseline) and 30 minutes, 90 minutes, and 3 hours after starting thrombolytic therapy. In 109 patients a CK-MB sample was obtained within 10 minutes of acute angiography (angio sample). At acute angiography the infarct-related artery was patent (Thrombolysis in Myocardial Infarction trial grade 2 to 3 flow) in 71%. Baseline CK-MB values were similar in patients with and without later reperfusion at acute angiography: 3 (0,8) ng/ml and 0 (0,4) ng/ml, respectively. At acute angiography, patients with successful reperfusion had higher CK-MB values [46 (20,138) ng/ml] compared with patients with persistent occlusion of the infarct-related artery [8 (3,63) ng/ml; p = 0.002).(ABSTRACT TRUNCATED AT 250 WORDS)
溶栓治疗后冠状动脉通畅情况对急性心肌梗死后的生存具有重要的预后意义。因此,在溶栓治疗后早期非侵入性识别患者的能力可能使其他策略,如辅助治疗或补救性血管成形术得以应用,以恢复梗死相关动脉的通畅。本研究探讨了快速肌酸激酶(CK)-MB检测结合选定的临床变量用于溶栓后再灌注的非侵入性检测。患者参与了一项评估加速纤溶酶原激活剂剂量方案的研究,在开始溶栓治疗后142(96,195)分钟(中位数及四分位数间距,即第25和75百分位数)进行急性血管造影时,通过首次血管造影注射评估通畅情况。在207例患者中,于开始溶栓治疗前(基线)以及治疗开始后30分钟、90分钟和3小时采集血清CK-MB样本,采用快速双单克隆抗体检测法进行测定。109例患者在急性血管造影后10分钟内采集了CK-MB样本(血管造影样本)。急性血管造影时,71%的患者梗死相关动脉通畅(心肌梗死溶栓试验2至3级血流)。急性血管造影时,有或无再灌注的患者基线CK-MB值相似:分别为3(0,8)ng/ml和0(0,4)ng/ml。急性血管造影时,成功再灌注的患者CK-MB值[46(20,138)ng/ml]高于梗死相关动脉持续闭塞的患者[8(3,63)ng/ml;p = 0.002]。(摘要截选至250字)